We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vitalea Science Announces Grant Award to Develop a Diagnostic Test Using MS Technologies
News

Vitalea Science Announces Grant Award to Develop a Diagnostic Test Using MS Technologies

Vitalea Science Announces Grant Award to Develop a Diagnostic Test Using MS Technologies
News

Vitalea Science Announces Grant Award to Develop a Diagnostic Test Using MS Technologies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vitalea Science Announces Grant Award to Develop a Diagnostic Test Using MS Technologies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vitalea Science, Inc has announced that it has received a Small Business Innovation Research grant from the NIH, to develop a medical diagnostic test to assess vitamin B12 malabsorption. The simple test intends to replace the Schillings test, the current standard, for assessing vitamin B12 malabsorption.

According to Company, the test will allow physicians to diagnose patients with vitamin B12 absorption problems before anemia, dementia and/or other permanent damage develops.

The method of 14C labeling of vitamin B12, using a modified strain of Salmonella bacteria, was developed by a team of scientists from the University of California, Davis, and Lawrence Livermore National Laboratory including Dr. Stephen Dueker, president of Vitalea Science. The method is protected by a patents filed by the University of California.

The work represents a growing area of clinical research, dubbed microdosing, where harmlessly small doses of drug candidates are paired with powerful accelerator mass spectrometry technologies to initially assess bio-activity in humans at very early stages of drug development, in lieu of lengthy preliminary animal testing.

"This award symbolizes our firm commitment to innovation and our relentless pursuit of Accelerator technology to achieve better tools for disease detection, and safer drugs for people," stated Dr. Vuong, Chief Operating Officer of Vitalea Science.

"We plan to have this test carried out on our compact particle accelerator, the bio-MICADAS, a joint development with Paul-Scherrer Institut in Zurich. We also intend to pursue Phase-II with UCDMC and other clinics to carry out the clinical trials later this year," said Dr Vuong.

Advertisement